keyword
MENU ▼
Read by QxMD icon Read
search

Landmark trial

keyword
https://www.readbyqxmd.com/read/29785289/what-is-the-role-of-wedge-resection-for-t1a-lung-cancer
#1
Sebron Harrison, Brendon Stiles, Nasser Altorki
Since 1995, lobar resection became the standard of care for medically fit patients with early stage lung cancer. This was based on the results of a single randomized trial comparing lobectomy and sublobar resection (SLR) in stage I lung cancer conducted by the lung cancer study group between 1982 and 1988. The conclusions of the study included a statistically significant tripling in loco-regional recurrence (LR) after limited resection but no difference between the two arms of the trial in systemic recurrence...
April 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29776804/hemicraniectomy-for-malignant-middle-cerebral-artery-syndrome-a-review-of-functional-outcomes-in-two-high-volume-stroke-centers
#2
Abhi Pandhi, Georgios Tsivgoulis, Nitin Goyal, Muhammad F Ishfaq, Shailesh Male, Efstathios Boviatsis, Jason J Chang, Ramin Zand, Konstantinos Voumvourakis, Lucas Elijovich, Anne W Alexandrov, Marc D Malkoff, Daniel Hoit, Adam S Arthur, Andrei V Alexandrov
BACKGROUND AND PURPOSE: Despite recent landmark randomized controlled trials showing significant benefits for hemicraniectomy (HCT) compared with medical therapy (MT) in patients with malignant middle cerebral artery infarction (MMCAI), HCT rates have not substantially increased in the United States. We sought to evaluate early outcomes in patients with MMCAI who were treated with HCT (cases) in comparison to patients treated with MT due to the perception of procedural futility by families (controls)...
May 15, 2018: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://www.readbyqxmd.com/read/29769238/strength-in-numbers-opportunities-for-enhancing-the-development-of-effective-treatments-for-type-1-diabetes-the-trialnet-experience
#3
Carla J Greenbaum, Cate Speake, Jeffrey Krischer, Jane Buckner, Peter A Gottlieb, Desmond A Schatz, Kevan C Herold, Mark A Atkinson
The early to mid-1980s were an inflection point in the history of type 1 diabetes research. Two landmark events occurred: the initiation of immune-based interventions seeking to prevent type 1 diabetes and the presentation of an innovative model describing the disorder's natural history. Both formed the basis for hundreds of subsequent studies designed to achieve a dramatic therapeutic goal-a means to prevent and/or reverse type 1 diabetes. However, the need to screen large numbers of individuals and prospectively monitor them using immunologic and metabolic tests for extended periods of time suggested such efforts would require a large collaborative network...
May 16, 2018: Diabetes
https://www.readbyqxmd.com/read/29769203/early-and-chronic-dipeptidyl-peptidase-iv-inhibition-and-cardiovascular-events-in-patients-with-type-2-diabetes-mellitus-after-an-acute-coronary-syndrome-a-landmark-analysis-of-the-examine-trial
#4
Abhinav Sharma, Christopher P Cannon, William B White, Yuyin Liu, George L Bakris, William C Cushman, Faiez Zannad
BACKGROUND: Antihyperglycemic therapies may increase the risk of cardiovascular events including hospitalization for heart failure. There is a paucity of data evaluating the cardiovascular safety of antihyperglycemic therapies in the high-risk period following an acute coronary syndrome (ACS). METHODS AND RESULTS: The EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial randomized 5380 patients who were 15 to 90 days post ACS to the dipeptidyl dipeptidase-IV (DPP-IV) inhibitor alogliptin versus placebo; mean follow-up was 18 months...
May 16, 2018: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29766304/operative-technique-in-robotic-pancreaticoduodenectomy-rpd-at-university-of-illinois-at-chicago-uic-17-steps-standardized-technique-lessons-learned-since-the-first-worldwide-rpd-performed-in-the-year-2001
#5
Pier Cristoforo Giulianotti, Alberto Mangano, Roberto E Bustos, Federico Gheza, Eduardo Fernandes, Mario A Masrur, Antonio Gangemi, Francesco M Bianco
BACKGROUND: Minimally invasive pancreaticoduodenectomy (MIPD) was introduced in the attempt to improve the outcomes of the open approach. Laparoscopic pancreaticoduodenectomy (LPD) was first reported by Gagner and Pomp (Surg Endosc 8:408-410, 1994). Unfortunately, due to its complexity and technical demand, LPD never reached widespread popularity. Since it was first performed by P. C. Giulianotti in 2001, Robotic PD (RPD) has been gaining ground among surgeons. MIPD is included as a surgical option in the latest NCCN Guidelines...
May 15, 2018: Surgical Endoscopy
https://www.readbyqxmd.com/read/29757894/immunosuppression-is-associated-with-clinical-features-and-relapse-risk-of-b-cell-posttransplant-lymphoproliferative-disorder-a-retrospective-analysis-based-on-the-prospective-international-multicenter-ptld-1-trials
#6
Heiner Zimmermann, Nina Babel, Daan Dierickx, Franck Morschhauser, Peter Mollee, Jan M Zaucha, Martin H Dreyling, Ulrich Dührsen, Petra Reinke, Gregor Verhoef, Marion Subklewe, Andreas Hüttmann, Thomas Tousseyn, Emmanuel Bachy, Ingeborg A Hauser, Corrado Tarella, Eric Van Den Neste, Olivier Gheysens, Ioannis Anagnostopoulos, Veronique Leblond, Hanno Riess, Sylvain Choquet, Ralf U Trappe
BACKGROUND: Current guideline recommendations for immunosuppression reduction after diagnosis of posttransplant lymphoproliferative disorder (PTLD) include stopping antimetabolites, reducing calcineurin inhibitors and maintaining corticosteroids. However, the effect of immunosuppression on PTLD relapse risk after up-to-date therapy is unclear. METHODS: This is a retrospective analysis of immunosuppression, patient baseline characteristics and relapse risk measured as landmark time to progression (TTP) starting 1 year after start of therapy in 159 patients with B cell PTLD after solid organ transplantation treated in the prospective, international, multicenter PTLD-1 trials with either sequential treatment (rituximab followed by CHOP chemotherapy) or risk-stratified sequential treatment (rituximab followed by rituximab or R-CHOP immunochemotherapy)...
May 11, 2018: Transplantation
https://www.readbyqxmd.com/read/29742382/deployment-of-preventive-interventions-time-for-a-paradigm-shift
#7
Katherine Pryor, Kevin Volpp
In 2002, Knowler et al. reported results of a landmark study — a large, randomized, controlled trial comparing a behavioral intervention with medical therapy in the prevention of diabetes. Over a mean follow-up period of 2.8 years, the lifestyle-modification program, known as the Diabetes..
May 10, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29736735/current-endovascular-approach-to-the-management-of-acute-ischemic-stroke
#8
REVIEW
Rakesh Khatri, Anantha R Vellipuram, Alberto Maud, Salvador Cruz-Flores, Gustavo J Rodriguez
PURPOSE OF REVIEW: The review provides an overview of current endovascular management of patients with acute ischemic stroke in the light of recent landmark trials proving unequivocal benefit of the intervention. RECENT FINDINGS: Several randomized trials looking at selective groups of patients presenting after an acute ischemic stroke due to large vessel occlusion in the anterior circulation demonstrated an overwhelming benefit of the endovascular treatment compared to intravenous thrombolysis, leading to expedited changes in the American Heart Association/American Stroke Association guidelines...
May 7, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29735190/potential-morbidity-reduction-with-proton-radiation-therapy-for-breast-cancer
#9
REVIEW
Lior Z Braunstein, Oren Cahlon
Proton radiotherapy confers significant dosimetric advantages in the treatment of malignancies that arise adjacent to critical radiosensitive structures. To date, these advantages have been most prominent in the treatment of pediatric and central nervous system malignancies, although emerging data support the use of protons among other anatomical sites in which radiotherapy plays an important role. With advances in the overall treatment paradigm for breast cancer, most patients with localized disease now exhibit long-term disease control and, consequently, may manifest the late toxicities of aggressive treatment...
April 2018: Seminars in Radiation Oncology
https://www.readbyqxmd.com/read/29720753/comparison-of-landmark-versus-pre-procedural-ultrasonography-assisted-midline-approach-for-identification-of-subarachnoid-space-in-elective-caesarean-section-a-randomised-controlled-trial
#10
Sangeeta Dhanger, Stalin Vinayagam, Bhavani Vaidhyanathan, Idhuyya Joseph Rajesh, Debendra Kumar Tripathy
Background and Aims: Identification of subarachnoid space in pregnant patients can pose a great challenge to anaesthesiologists. This study was designed to compare conventional landmark technique with pre-procedural ultrasonography-assisted midline approach for identification of the subarachnoid space in elective caesarean section. Methods: After institute ethics committee approval and written informed consent, 100 parturients scheduled for elective caesarean section under spinal anaesthesia were included in this prospective randomised control trial and divided into Group L ( n = 50) (landmark technique) and Group U ( n = 50) (ultrasound-guided technique)...
April 2018: Indian Journal of Anaesthesia
https://www.readbyqxmd.com/read/29687191/sacubitril-valsartan-from-clinical-trials-to-real-world-experience
#11
REVIEW
Joanna M Joly, Akshay S Desai
PURPOSE OF REVIEW: Compared to enalapril, use of angiotensin-receptor blocker and neprilysin inhibitor sacubitril/valsartan to treat patients with heart failure and reduced ejection fraction (HFrEF) is associated with substantial reductions in both cardiovascular mortality and heart failure progression. The purpose of this review is to discuss the real-world experience of sacubitril/valsartan. RECENT FINDINGS: In the years following the publication of the landmark PARADIGM-HF trial in 2014 and its subsequent FDA approval, a growing evidence base supports the safety and efficacy of sacubitril/valsartan in a broad spectrum of patients with HFrEF...
April 23, 2018: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29684329/vision-outcomes-following-anti-vascular-endothelial-growth-factor-treatment-of-diabetic-macular-edema-in-clinical-practice
#12
Nancy M Holekamp, Joanna Campbell, Arghavan Almony, Herbert Ingraham, Steven Marks, Hitesh Chandwani, Ashley L Cole, Szilárd Kiss
PURPOSE: To determine monitoring and treatment patterns, and vision outcomes in real-world patients initiating anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME). DESIGN: Retrospective interventional cohort study. METHODS: SETTING: Electronic medical record analysis of Geisinger Health System data. STUDY POPULATION: 110 patients (121 study eyes) initiating intravitreal ranibizumab or bevacizumab for DME during January 2007‒May 2012, with baseline corrected visual acuity of 20/40‒20/320, and ≥1 ophthalmologist visits during follow-up...
April 20, 2018: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29674324/indications-for-the-performance-of-intracranial-endovascular-neurointerventional-procedures-a-scientific-statement-from-the-american-heart-association
#13
REVIEW
Clifford J Eskey, Philip M Meyers, Thanh N Nguyen, Sameer A Ansari, Mahesh Jayaraman, Cameron G McDougall, J Kevin DeMarco, William A Gray, David C Hess, Randall T Higashida, Dilip K Pandey, Constantino Peña, Hermann C Schumacher
Intracranial endovascular interventions provide effective and minimally invasive treatment of a broad spectrum of diseases. This area of expertise has continued to gain both wider application and greater depth as new and better techniques are developed and as landmark clinical studies are performed to guide their use. Some of the greatest advances since the last American Heart Association scientific statement on this topic have been made in the treatment of ischemic stroke from large intracranial vessel occlusion, with more effective devices and large randomized clinical trials showing striking therapeutic benefit...
April 19, 2018: Circulation
https://www.readbyqxmd.com/read/29667581/relation-between-bioresorbable-scaffold-sizing-using-qca-dmax-and-long-term-clinical-outcomes-in-1-232-patients-from-3-study-cohorts-absorb-cohort-b-absorb-extend-and-absorb-ii
#14
Yuki Katagiri, Yoshinobu Onuma, Taku Asano, Ply Chichareon, Carlos Collet, Yosuke Miyazaki, Jan J Piek, Joanna J Wykrzykowska, Alexandre Abizaid, John A Ormiston, Bernard Chevalier, Patrick W Serruys
AIMS: This study sought to investigate the long-term clinical outcomes related to scaffold sizing based on quantitative coronary angiography. METHODS AND RESULTS: A total of 1,248 patients who received Absorb bioresorbable scaffolds in the ABSORB Cohort B, ABSOR EXTEND, ABSORB II trials were included in the analysis. The incidence of MACE (a composite of cardiac death, any myocardial infarction [MI], and ischemia-driven target lesion revascularization [ID-TLR]) was analysed according to the Dmax subclassification of oversized scaffold group versus non-oversized (any undersize) scaffold group...
April 17, 2018: EuroIntervention
https://www.readbyqxmd.com/read/29652672/early-discontinuation-of-prasugrel-or-clopidogrel-in-acute-coronary-syndromes-insights-from-the-trilogy-acs-trial
#15
Andrew T Yan, Matthew T Roe, Megan Neely, Derek D Cyr, Harvey White, Keith A A Fox, Dorairaj Prabhakaran, Paul W Armstrong, Erik M Ohman, Shaun G Goodman
BACKGROUND: In the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial of patients with non-ST-segment elevation acute coronary syndrome managed medically without revascularization, treated with prasugrel versus clopidogrel for less than or equal to 30 months after index acute coronary syndrome, post-hoc analyses showed a divergence of treatment effect in favor of prasugrel after 12 months. Potential influential factors, including a potential late treatment effect after early study drug discontinuation in the intention-to-treat analysis, have not been explored...
April 12, 2018: Coronary Artery Disease
https://www.readbyqxmd.com/read/29644451/emerging-therapies-in-metastatic-prostate-cancer
#16
REVIEW
Daniel W Sonnenburg, Alicia K Morgans
PURPOSE OF REVIEW: In the last decade, there have been multiple landmark therapeutic advances for the treatment of metastatic prostate cancer, both in the castration-resistant and hormone-sensitive setting. In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy. RECENT FINDINGS: Several landmark studies for men with metastatic hormone-sensitive prostate cancer demonstrated improvement in overall survival with the addition of docetaxel chemotherapy or abiraterone acetate to standard androgen deprivation therapy...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29628705/ultrasound-guided-versus-landmark-guided-corticosteroid-injection-in-patients-with-rotator-cuff-syndrome-randomised-controlled-trial
#17
Himanshu Bhayana, Puneet Mishra, Anupama Tandon, Amite Pankaj, Rohit Pandey, Raskesh Malhotra
Objective: Impingement syndrome is the most common differential in a patient presenting to an orthopaedic OPD with shoulder pain. Impingement syndrome is often managed with subacromial corticosteroid injection, which can be instilled using either landmark guided (LMG) approach or with the assistance of ultrasound (US). This study was envisaged to enquire whether ultrasound assistance improves the accuracy, efficacy or safety profile of the injection. Methods: 60 patients of rotator cuff syndrome underwent diagnostic ultrasound...
March 2018: Journal of Clinical Orthopaedics and Trauma
https://www.readbyqxmd.com/read/29628554/comparison-of-ultrasound-with-peripheral-nerve-stimulator-guided-technique-for-supraclavicular-block-in-upper-limb-surgeries-a-randomized-controlled-trial
#18
Vinu Mervick Alfred, Gnanasekaran Srinivasan, Mamie Zachariah
Background: The supraclavicular approach is considered to be the easiest and most effective approach to block the brachial plexus for upper limb surgeries. The classical approach using the anatomical landmark technique was associated with higher failure rates and complications. Ultrasonography (USG) guidance and peripheral nerve stimulator (PNS) have improved the success rates and safety margin. Aims: The aim of the present study is to compare USG with PNS in supraclavicular brachial plexus block for upper limb surgeries with respect to the onset of motor and sensory blockade, total duration of blockade, procedure time, and complications...
January 2018: Anesthesia, Essays and Researches
https://www.readbyqxmd.com/read/29627360/the-occult-hemodynamically-significant-left-main-stenosis-in-the-asymptomatic-patient-reconciling-the-visual-functional-mismatch-a-case-report-and-review-of-screening-appropriateness-and-assessment-of-left-main-in-patient-with-multi-vessel-cad
#19
REVIEW
Maryam Balouch, Jennifer Ballard-Hernandez, Min Kim, Arnold Seto, Morton Kern
We present a 40 year old asymptomatic man with mild left main artery narrowing who demonstrated extreme discordance between symptom presentation and ischemic burden i.e. visual (angiographic) and ischemic (functional) mismatch. The use of an appropriately selected screening stress test can lead to an appropriate decision for revascularization, supported by landmark risk assessment documents and revascularization trials.
February 21, 2018: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/29623227/fulminant-diabetes-in-a-patient-with-advanced-melanoma-on-nivolumab
#20
Nora Chokr, Hafsa Farooq, Elizabeth Guadalupe
Background: Anti-PD-1 agents were approved for advanced melanoma after the landmark trial Checkmate-037. Anti-PD-1 agents can breach immunologic tolerance. Fulminant diabetes is an immune endocrinopathy that results from a violent immune attack leading to complete destruction of pancreatic beta cells in genetically predisposed people. We present a rare case of fulminant diabetes precipitated by anti-PD-1 immunotherapy. Case: A 61-year-old male with advanced melanoma presented with a three-day history of nausea, vomiting, and malaise...
2018: Case Reports in Oncological Medicine
keyword
keyword
11836
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"